This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignee: Yale University. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Matthew Dong: Advancing T-Cell Immunotherapy Research
Introduction
Matthew Dong is an inventor based in San Francisco, California, whose patent work focuses on approaches to improve T-cell activity and support cancer immunotherapy. He is associated with Yale University and is named on 3 patents.
Latest Patents
Dong’s recent patent work includes “Compositions and Methods for High-Throughput Activation Screening to Boost T Cell Effector Function.” The invention describes dead-guide RNA (dgRNA) libraries and methods for their use in immunology and immunotherapy. It also covers engineered primary or chimeric antigen receptor (CAR) T cells that overexpress Prodh2, Ccnblip1, Sreklip1, Wdr37, or a fragment of one of these proteins.
Another recent patent is “Compositions for Identification of Membrane Targets for Enhancement of T Cell Activity Against Cancer.” It describes compositions and methods for identifying membrane targets that may enhance T-cell activity against disease and strengthen anti-tumor responses. The disclosed applications include cancer, with glioblastoma and breast cancer noted as examples.
Career Highlights
Dong’s listed inventions address two complementary research goals: identifying targets that may improve T-cell responses and developing screening or engineering methods to enhance T-cell effector function. His work is associated with Yale University.
Collaborations
Sidi Chen and Ryan D. Chow are identified as Dong’s coworkers. Their shared institutional context connects their work to research in immunology and cancer-focused T-cell approaches.
Conclusion
Matthew Dong’s patent portfolio reflects a focus on methods and compositions for strengthening T-cell activity, with potential applications in cancer immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
